We are live on ! Find out more
MLNT

Melinta Therapeutics, Inc. Common Stock
MLNT

Delisted

MLNT was delisted on the 10th of January, 2020.

Back to rankings

83 hedge funds and large institutions have $136M invested in Melinta Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 28 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 18

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

6% more funds holding

Funds holding: 78 → 83 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

26% less capital invested

Capital invested by funds: $183M → $136M (-$47M)

73% less call options, than puts

Call options by funds: $256K | Put options by funds: $951K

Holders
83
Holders Change
+5
Holders Change %
+6.41%
% of All Funds
1.9%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
28
Reduced
18
Closed
13
Calls
$256K
Puts
$951K
Net Calls
-$695K
Net Calls Change
+$290K

Top Buyers

1
DM
Deerfield Management
New York
+$41.1M
2
OH
Oikos Holdings
New York
+$26.3M
3
FTIOP
Fiduciary Trust International of Pennsylvania
Pennsylvania
+$3.94M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.94M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$3.87M

Top Sellers

1
TCIM
TIAA CREF Investment Management
New York
-$696K
2
ARTA
A.R.T. Advisors
New York
-$525K
3
BCM
Bridgeway Capital Management
Texas
-$512K
4
BG
Bellevue Group
Switzerland
-$507K
5
Deutsche Bank
Deutsche Bank
Germany
-$405K
Name Holding Trade Value Shares
Change 		Change in
Stake
OH
1
Oikos Holdings
New York
$64.6M +$26.3M +400,000 +30%
DM
2
Deerfield Management
New York
$23.1M +$41.1M +625,569 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$7.32M – – –
BlackRock
4
BlackRock
New York
$6.34M +$3.33M +50,589 +42%
Vanguard Group
5
Vanguard Group
Pennsylvania
$6.08M +$3.94M +59,875 +57%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$3.52M +$602K +9,156 +11%
Millennium Management
7
Millennium Management
New York
$3.31M +$2.21M +33,560 +60%
FTIOP
8
Fiduciary Trust International of Pennsylvania
Pennsylvania
$2.22M +$3.94M +59,884 New
Wellington Management Group
9
Wellington Management Group
Massachusetts
$2.17M +$3.87M +58,785 New
SFM
10
Sphera Funds Management
Israel
$1.8M +$577K +8,779 +22%
State Street
11
State Street
Massachusetts
$1.43M +$410K +6,237 +19%
Northern Trust
12
Northern Trust
Illinois
$1.23M +$709K +10,777 +48%
Man Group
13
Man Group
United Kingdom
$1.14M +$2.02M +30,708 New
Stifel Financial
14
Stifel Financial
Missouri
$1.12M +$1.99M +30,283 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.03M +$779K +11,853 +74%
SDIC
16
South Dakota Investment Council
South Dakota
$962K – – –
Renaissance Technologies
17
Renaissance Technologies
New York
$871K +$465K +7,073 +43%
EP
18
Eversept Partners
New York
$569K +$1.01M +15,367 New
Charles Schwab
19
Charles Schwab
California
$553K +$356K +5,410 +57%
Morgan Stanley
20
Morgan Stanley
New York
$527K +$376K +5,724 +67%
Deutsche Bank
21
Deutsche Bank
Germany
$458K -$405K -6,156 -33%
PAM
22
Panagora Asset Management
Massachusetts
$418K -$151K -2,304 -17%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$413K +$243K +3,692 +49%
PAI
24
Palo Alto Investors
California
$375K – – –
VEA
25
Virtus ETF Advisers
New York
$363K +$355K +5,395 +122%
1
2 3 4

MLNT Hedge Fund Activity: Q1 2018 in Review

83 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics, Inc. Common Stock (MLNT) for Q1 2018, worth a combined $136M — down 26% from $183M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new MLNT positions and 13 closed out — a net gain of 7 holders — while 28 added to existing stakes and 18 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $41.1M. The largest seller was TIAA CREF Investment Management, cutting an estimated $696K.

  • 83 institutional investors held Melinta Therapeutics, Inc. Common Stock (MLNT) as of Q1 2018, up from 78 in Q4 2017.
  • Funds reported $136M of Melinta Therapeutics, Inc. Common Stock stock for Q1 2018, down 26% quarter-over-quarter.
  • 20 funds opened new Melinta Therapeutics, Inc. Common Stock positions in Q1 2018 and 13 closed out, a net change of +7 holders.
  • The largest Melinta Therapeutics, Inc. Common Stock buyer in Q1 2018 was Deerfield Management, an estimated $41.1M added.
  • The largest Melinta Therapeutics, Inc. Common Stock seller in Q1 2018 was TIAA CREF Investment Management, an estimated $696K sold.

Based on aggregated 13F filings for Q1 2018.